Disturbances of heme synthesis, and thereby porphyrin metabolism and excretion, are well known in patients with chronic liver disease of various aetiology such as heavy metal exposure, liver cirrhosis and chronic hepatitis (Doss & Martini, 1977) . Also in bone marrow diseases such as leukaemia, pernicious and haemolytic anaemias such disturbances have been reported. The usual findings in liver and bone marrow diseases have been that of an asymptomatic patient with isolated coproporphyrinuria. A number of case reports have been published on patients with liver tumours, benign as well as malignant including liver metastases, coincident with symptomatic hepatic porphyria clinically manifest as porphyria cutanea tarda (PCT) (Thompson et al., 1970; Waddington, 1972) . In some of these cases a reduced uroporphyrinogen decarboxylase activity has been detected and this enzyme defect has been regarded as a paraneoplastic phenomenon caused by liver damage (Doss & Martini, 1977 ). An increased risk of hepatocellular cancer (HCC) has been reported in patients with PCT (Berman & Braun, 1962; Kordac, 1972; Salata et al., 1985) . Liver cancer in PCT patients has almost invariably developed in cirrhotic livers, cirrhosis thought to be the prerequisite for carcinogenesis. Agents associated with an increased risk of HCC such as alcohol, steroid hormones and aflatoxin are potent porphyrinogenic substances (Kappas & Granick, 1968; Sherlock, 1981; Zawirska & Bednarz, 1981) . In animal experimental models of porphyria hexachlorobenzene (HCB) has been widely used (Koss et al., 1983; Wainstok de Calmanovici et al., 1984) . HCB is also a liver carcinogen in several animal species (Cabral et al., 1977; 1979; Smith & Cabral, 1980) .
Recently an association between porphyria acuta intermittens (PAI) and HCC has been reported (Lithner & Wetterberg, 1984; Hardell et al., 1984; Kaupinnen & Mustajoki, Unpublished) . In our case control study 3 cases of PAI were identified among the 83 patients with HCC versus none among the 200 controls (Hardell et al., 1984) . PAI is an inborn error of metabolism inherited as a dominant trait and characterized by a reduced activity of the ratelimiting enzyme in heme synthesis, uroporphyrinogen-l-synthetase. The disease is often manifested at the age of puberty. The clinical picture of an acute attack is characterized by abdominal pain, neurological symptoms, changes in electrolytes and marked increase in the excretion of two precursors in heme synthesis, amino levulinic acid (ALA) and porphobilinogen (PBG). PAI is a rare disease worldwide and our region is actually' one of the high incidence areas with an estimated prevalence of 1 case per 1000 inhabitants (Waldenstr6m, 1969) .
A mapping of the pedigrees of 2 families has been performed and is presented in Figures la,b .
In total 5 cases of HCC in persons with PAI were identified in these 2 families. The age at diagnosis was: 66, 67, 69, 69 and 70 years. The male in the first generation in family 1 was the carrier of (Hardell et al., 1984) , diagnoses were based on histopathological examination of biopsy and autopsy material. Various hypotheses can be postulated for the accumulation of HCC in families with PAI. The genetic locus for uroporphyrinogen-1-synthetase is located to the long arm of chromosome 11 (Meisler et al., 1980) . This point mutation could be associated with an oncogene responsible for the high risk of HCC development in these persons. No data are available regarding this, however. Another theory is that porphyrins are carcinogenic per se. This hypothesis can be supported by: 1. Porphyrins have photochemical cytotoxic properties and upon illumination form highly reactive oxygen radicals (Weishaupt et al., 1976; Brault et al., 1985) . This effect has been used to treat cutaneous and subcutaneous metastases of various cancers in humans (Wile et al., 1984) . 2. In a recent study of HCB-induced hepatocarcinogenesis rats were fed HCB in diet for 90
weeks (Smith et al., 1985) . Both sexes showed a decrease in uroporphyrinogen decarboxylase activity. Massive porphyria developed in females but not in males. After 90 weeks of HCB treatment 100% of the female rats developed multiple liver tumours versus only 16% of the male rats. Analysis of HCB content in liver tissue showed no differences between males and females. These findings indicate that HCB exerts its hepatocarcinogenic action via porphyrins. 3. In a study of patients with PCT 17 out of 342 patients followed in the years 1954-69 developed HCC. Another group of 367 PCT patients were treated with chloroquine 250mg p.o. twice a week and followed in the years 1969-83. Of these only 3 developed HCC. The cutaneous symptoms as well as the urine excretion of uroporphyrin and coproporphyrin were significantly lowered in the chloroquine group (Kordac et al., unpublished) . 4. In a study of porphyrin metabolism a group of patients with liver cirrhosis and another group with liver cirrhosis and HCC were compared with healthy controls (Udagawa et al., 1984) . A significant increase of uroporphyrin and coproporphyrin excretion in urine was found in both patient groups. Furthermore HCC patients showed significantly higher excretion of porphyrins compared with patients with only liver cirrhosis. No correlation between porphyrin excretion and liver function tests was found.
The increased risk for HCC in persons with hepatic porphyrias and results from experimental investigations have initiated further studies on porphyrins in hepatocarcinogenesis.
